- Trial phase
- Phase 1b (proof-of-concept completed); Phase 2 (celiac disease) ongoing
- Time to market
- Likely 3-5+ years from 2026, pending Phase 2 celiac readout and Phase 3 development. FB102 is currently in Phase 1b/2-stage development with argenx's resources expected to accelerate the pipeline post-acquisition.
- Why 4/10
- FB102 is a pipeline-in-a-product asset being acquired by argenx (ARGX) and does not have a single near-term binary catalyst (PDUFA or pivotal readout) within the next ~12 months that would single-handedly drive ARGX's stock. The next hard catalyst is Phase 2 celiac data (H2 2026), but this is one of many pipeline programs at a ~$53B company with an approved blockbuster, thus impactScore is a 4.
For ARGX investors, FB102 is a bolt-on pipeline asset that adds long-term optionality but is not a near-term binary driver given argenx's ~$53B market cap and $1.5B H1 2026 VYVGART revenue. Watch for Phase 2 celiac disease readout (H2 2026) and the deal closing (expected by late Q3). For FBRX holders, the stock trades near the $77 offer price, the arbitrage spread hinges on antitrust clearance and deal timing.
Price Chart
Executive Summary
FB102 is a first-in-class anti-CD122 antibody developed by Forte Biosciences (FBRX) with clinical proof-of-concept in vitiligo and celiac disease, and FDA Fast Track designation for celiac. In July 2026, argenx (ARGX) announced it is acquiring Forte for $77/share in cash (~$2.2B total equity), funded from cash on hand, expected to close in Q3 2026. For argenx, FB102 represents a strategic pipeline expansion beyond FcRn blockade into T-cell/NK-cell mediated autoimmune diseases, a new mechanism with multiple shot-on-goal opportunities. The deal already has regulatory momentum (tender offer commenced Aug 6, shareholder meeting Sep 17).
How It Works
FB102 is an antibody that blocks CD122, a protein on the surface of immune cells called T cells and NK cells. By blocking this target, FB102 is designed to dial down the overactive immune responses that cause autoimmune diseases like vitiligo (white patches on skin), celiac disease (immune reaction to gluten), and alopecia areata (hair loss). It works through a different pathway than argenx's existing drug VYVGART, which blocks FcRn and clears harmful antibodies.
Trial Status
FB102 has completed Phase 1b proof-of-concept studies showing positive data in vitiligo. The drug has also demonstrated clinical proof-of-concept in celiac disease. A Phase 2 celiac disease trial is ongoing with data expected H2 2026. FDA Fast Track designation was granted for celiac disease. The asset is being acquired by argenx and will be integrated into their immunology pipeline.
The Two-Sided Case
Upcoming Catalysts
- Closing of argenx/Forte acquisition (Q3 2026, expected by end of September after Sep 17 EGM)
- Phase 2 celiac disease topline data (H2 2026)
- Potential expansion into alopecia areata and other autoimmune indications
Source Filing
The SecBot filing or press-release report that triggered this drug report:
argenx SE Press Release ARGX ·Originating report